Intranet Campus web

Study of metabolic and cardiovascular diseases within project CarDia

Our laboratory is involved in the research activities of the CarDia project (2022 – 2025; see below)


In particular, we focus on the following research areas:

  1. Synthesis and study of the effects of new hepatoselective analogues of human insulin for the potential treatment of type 1 and type 2 diabetes mellitus (M. Rossmeisl in collaboration with J. Jiracek at the Institute of Organic Chemistry and Biochemistry CAS).
  2. Testing NRF2 activators to improve adipose tissue function and their use in stimulating the synthesis and secretion of insulin-sensitizing lipokines in the context of exercise (M. Rossmeisl in collaboration with L. Rossmeislova at the 3rd Faculty of Medicine, Charles University).
  3. Use of novel synthetic analogues of natural neuropeptides as potential drugs against obesity and type 2 diabetes mellitus (J. Kopecky in collaboration with L. Maletinska at the Institute of Organic Chemistry and Biochemistry CAS).
  4. Role of adipose tissue metabolim in development of cardiac cachexia (J. Kopecky in collaboration with V. Melenovsky and M. Haluzik at the Institute of clinical and experimental medicine).


Related publication: Brezinova et al. 2020 BBA-Mol Cell Biol LJanovska et al. 2020 J Cachexia, Sarcopenia Muscle


Conference Bioenergetics 2024, May 20-22

Project supported by National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) - Funded by the European Union – Next Generation EU.